David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...
The FDA has accepted the sBLA for nivolumab (Opdivo) plus ipilimumab (Yervoy) as a potential first-line treatment for advanced MSI-H or dMMR CRC.
The primary endpoint was progression-free survival (PFS; nivolumab/ipilimumab vs chemotherapy and nivolumab/ipilimumab vs nivolumab monotherapy). Findings showed the risk of disease progression or ...
Combination treatment with nivolumab and cabozantinib provides long-term benefits over sunitinib in patients with advanced RCC, according to final results from the CheckMate 9ER trial.
HealthDay on MSN13d
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer ...
Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.
In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback